While semaglutide itself doesn't cause Raynaud's or vascular disease, the metabolic cooling effect could amplify existing discomfort
Methodology and Sources This analysis is based on publicly available sources as of December 26, 2025: FDA communications: Compounding safety alerts, prescribing information, and regulatory guidance Novo Nordisk announcements: Wegovy pill approval, OASIS 4 trial results, pricing disclosures Independent reporting and primary sources: ABC News coverage and Novo Nordisk's announcement on December 22, 2025 FDA oral Wegovy approval MEDVi terms and disclosures: Platform structure, pricing, and regulatory disclaimers Key Sources Cited: ABC News: "FDA approves Wegovy pill for weight loss" (December 22, 2025) Novo Nordisk: Official press release on FDA approval and OASIS 4 trial data (December 22, 2025) FDA Safety Communications: 20242025 alerts on compounded semaglutide dosing errors All regulatory references are based on FDA publications and third-party reporting available at the time of publication
The fact that its tested and made in the U.S
Serving Lakeway, Bee Cave, Spicewood, Westlake, Lake Travis & greater Austin
Mol Brain 17(1):93 Gonzalez-Burgos I, Feria-Velasco A (2008) Serotonin/dopamine interaction in memory formation
Mikol, J
